Proliferative vitreoretinopathy: Immunoreactive endothelin-1

Annals of Ophthalmology - Tập 36 - Trang 24-28 - 2004
Manuela Roldán-Pallarés1, Roquel Rollín2, Rosa Bernal2, Ainhoa Ripodas2, José Angel Marañón2, Arturo Fernández-Cruz3, Raquel Fernández-Durango2
1The Department of Ophthalmology, Universidad Compuutense, Madrid, Spain
2the Research Unit, Universidad Compuutense, Madrid, Spain
3The Department of Internal Medicine at the Hospital Clínico San Carlos, Universidad Compuutense, Madrid, Spain

Tóm tắt

Endothelin-1 is a potent vasoconstrictive and neural peptide functionally active in the eye. We demonstrated that the concentration of immunoreactive endothelin-1 in subretinal fluid was higher in patients with proliferative vitreoretinopathy (PVR) vs. uncomplicated retinal detachment. No differences in plasma concentrations of immunoreactive endothelin-1 were found. Intraocular synthesis of endothelin-1 may play a role in the pathogenesis of PVR.

Tài liệu tham khảo

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by endothelial cells. Nature (London). 1988; 332:411–5. Battistini B, Chailler P, D'Orleans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides. 1993;14:385–9. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of cDNA encoding and endothelin receptor. Nature (London) 1990;348:730–2. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of cDNA encoding a non isopeptide selective subtype of endothelin receptor. Nature (London) 1990;348:732–5. Sakurai T, Yanagisawa M, Masaki T. Molecular characterisation of endothelin receptor. Trends Pharmacol Sci. 1992;13:103–8 Warner TD, Mitchell JA, De Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovas Pharmacol. 1989;13:S85-S88. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863–7. MacKumber MW, Jampel HD, Snyder SH. Ocular effect of endothelin. Arch Ophthalmol. 1991;109:705–9. Chakravarthy U, Douglas AJ, Bailie JR, McKibben B, Archer DB. Immunoreactive endothelin distribution in ocular tissues. Invest Ophthalmol Vis Sci. 1994;35:2448–54. Ripodas A, de Juan JA, Roldán-Pallarés M, et al. Localisation of Endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and procine eye. Evidence for endothelin-1 expression in astrocytes. Brain Res. 2001;912:137–143. Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Arch Opthalmol 1979;97:480–3. The Retinal Society Terminology Commitee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121–5. Ryan SJ. The pathophysiology of proliferative vitreoretinopathy and its management. Am J Ophthalmol. 1985;100:188–93. Smith-Thomas L, Haycock JW, Metcalfe R. Involvement of calcium in retinal pigment epithelial cell proliferation and pigmentation. Curr Eye Res. 1998;8:813–822. Lincoff H, Baras I, McLean JM. Modifications to the Custodis procedure for retinal detachment. Arch Ophthalmol. 1965;73:160–3 Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159–165. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265–275. Huerva V, Sinues B, Canto LM, Lanuza J, Palomar A Apoprotein B in subretinal fluid. Int Ophthalmol. 1996-97;20:181–5. De Juan JA, Moya FJ, García de la Coba M, Fernández-Cruz A, Fernández-Durango R. Identification and characterization of endothelin receptor subtype B (ETB) in rat retina. J Neurochem. 1993;61:1113–9. Limb GA, Little BC, Meager A. Cytokines in proliferative vitreoretinopathy. Eye. 1991;5:686–693. Kauffmann DJ, Van Meurs JC, Mertens DA, Peperkamp E, Master C, Gerritsen ME. Cytokines in vitreous humor: Interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;35:900–6. Kosnosky W, Li TH, Pakalnis VA, Fox A, Hunt RC. Interleukin-1-beta changes the expression of metalloproteinases in the vitreous humor and induces membrane formation in eyes containing preexisting retinal holes. Invest Ophthalmol Vis Sci. 1994;35:4260–7. Schweigerer L, Malerstein B, Neufeld G, Gospodarowicz D. Basic fibroblast growth factor is synthesized in cultured retinal pigment epithelial cells. Biochem Biophys Res Commun. 1987;143:934–40. Baudouin C, Fredj-Reygrobellet D, Brignole F, Negre F, Lapalus P. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res. 1993;25:52–9. Grisanti S, Wiedermann P, Heimann K. Die proliferative vitreoretinopathie. Zur bedutung des proteintransfers durch die blutretia-schranke. Ophtalmologie. 1993;90:468–71. Grisanti S, Guidry C, Heimann K. Contraction of extracellular matrix by transdifferentiated retinal pigment epithelial cells, inducers and inhibitors. Opthalmologe. 1996;93:709–13. Matsura A, Kawashima S, Yamochi W, et al. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun. 1997; 235:713–6. Connor TB Jr, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J. Clin Invest. 1989;83:1661–6.